www.sppirx.com
Open in
urlscan Pro
50.28.14.90
Public Scan
Submitted URL: http://www.sppirx.com/
Effective URL: https://www.sppirx.com/
Submission: On October 17 via api from US — Scanned from DE
Effective URL: https://www.sppirx.com/
Submission: On October 17 via api from US — Scanned from DE
Form analysis
1 forms found in the DOM.
<form action=".">
<input type="search" class="st-default-search-input" placeholder="start typing search & press enter" autocomplete="off" autocorrect="off" autocapitalize="off">
</form>
Text Content
* * Our Company * Our Company * Company Philosophy * Corporate Compliance * Management * Responsibility * Board of Directors * PRODUCTS * ROLVEDON™ (eflapegrastim-xnst) * Development Pipeline * Pipeline * Poziotinib * Clinical Trials * Glossary * Investor Relations * Investor Relations * Press Releases * Events and Presentations * Corporate Governance * Corporate Governance * Management * Board of Directors * Committee Composition * Insider Transactions * Annual Report and Proxy Information * Financial Information * Financial Information * SEC Filings * 10K Annual Reports * Quarterly Results * Financial Statements * Stock Information * Stock Information * Historic Stock Lookup * Investment Calculator * Stock-Split History * Analyst Coverage * Ownership Profile * Investor FAQs * Medical Affairs * Medical Affairs * Medical Information * Grants * Expanded Access Program * Careers * Contact Us * * * * * * OFFERING HOPE Learn more about Spectrum's Late-Stage Products * SMALL COMPANY SPIRIT, BIG COMPANY PERFORMANCE Our people are our best asset. Learn more. * MAKING A DIFFERENCE IN THE LIVES OF PATIENTS EVERY DAY * FOCUSED ON VALUE Spectrum has a proven record of success. Learn more. OUR COMMITMENT TO PATIENTS At Spectrum Pharmaceuticals, Inc., we bring the expertise and passion for excellence of our team to acquire, develop and commercialize novel and targeted pharmaceuticals for unmet medical needs while building value for our shareholders. More FOCUSED ON THE FUTURE Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted drug products, with a primary focus in hematology and oncology. Spectrum has a strong track record for in-licensing and acquiring differentiated drugs, and for clinical development. Spectrum has a late-stage pipeline that has the potential to transform the company. SPECTRUM HAS ONE FDA APPROVED DRUG AND ONE IN ADVANCED DEVELOPMENT: ROLVEDON™ (EFLAPEGRASTIM-XNST) INJECTION Full Prescribing Information » Learn more » POZIOTINIB Poziotinib for a mutation in Non Small Cell Lung Cancer (NSCLC), and for patients with breast cancer. Learn more » EXPANDING PATIENT OPTIONS Our passion to deliver additional options for patients suffering from cancer is behind every action we take. We will work to understand their needs and develop new and innovative therapies that offer hope for improved disease outcomes. Learn more about the Spectrum philosophy. The Spectrum Philosophy COMPANY HIGHLIGHTS View All Press Releases September 23, 2022 SPECTRUM PHARMACEUTICALS ANNOUNCES DEBT FINANCING AGREEMENT WITH SLR CAPITAL PARTNERS WITH $30 MILLION FUNDED AT CLOSING Read More September 22, 2022 SPECTRUM PHARMACEUTICALS PROVIDES UPDATE ON POZIOTINIB FOLLOWING FDA ONCOLOGIC DRUGS ADVISORY COMMITTEE MEETING Read More September 10, 2022 SPECTRUM PHARMACEUTICALS ANNOUNCES DATA FROM POSTER PRESENTATION FOR POZIOTINIB IN NSCLC PATIENTS WITH G778_P780DUP HER2 EXON 20 MUTATIONS AT ESMO CONGRESS 2022 Read More OUR COMPANY * Company Philosophy * Corporate Compliance * Management * Responsibility * Board of Directors PRODUCTS * ROLVEDON™ (eflapegrastim-xnst) DEVELOPMENT PIPELINE * Pipeline * Poziotinib * Clinical Trials * Glossary INVESTOR RELATIONS * Press Releases * Events and Presentations * Corporate Governance * Annual Report and Proxy Information * Financial Information * Stock Information * Investor FAQs MEDICAL AFFAIRS * Medical Information * Grants * Expanded Access Program CAREERS CONTACT US -------------------------------------------------------------------------------- This Web site contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and in reliance upon the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on the beliefs of the Company's management as well as assumptions made by and information currently available to the Company's management. Readers should not put undue reliance on these forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Spectrum Pharmaceuticals, Inc.'s actual results may differ materially from the results projected in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed in the Company's most recent Form 10-K and 10-Qs. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this filing except as required by law. ROLVEDON is a trademark of Spectrum Pharmaceuticals, Inc. © 2022 Spectrum Pharmaceuticals, Inc. All Rights Reserved. PP-ALL-00-0052 * Site Map * Privacy Policy * Terms of Use * Contact Us Accept Strictly Necessary Cookies Only PRIVACY PREFERENCE CENTER When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer. More information Allow All MANAGE CONSENT PREFERENCES STRICTLY NECESSARY COOKIES Always Active These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information. View Vendor Details MEASUREMENT COOKIES Measurement Cookies These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance. View Vendor Details MARKETING COOKIES Marketing Cookies These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising. View Vendor Details Back Button PERFORMANCE COOKIES Vendor Search Search Icon Filter Icon Clear checkbox label label Apply Cancel Consent Leg.Interest checkbox label label checkbox label label checkbox label label * View Cookies * Name cookie name Reject All Confirm My Choices By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. Cookies Settings Reject All Accept All Cookies Accept Strictly Necessary Cookies Only